Sign In
Buy GTBP
$0.439
-0.0279 (-5.97%)
At Close: Jun 03, 2026
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
09:15am, Tuesday, 21'st May 2024
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for t
What made GT Biopharma stock more than double on Monday?
10:43am, Monday, 20'th May 2024
GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn't been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company.
Why Is GT Biopharma (GTBP) Stock Up 143% Today?
08:40am, Monday, 20'th May 2024
GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of G
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
05:00pm, Wednesday, 15'th May 2024
BRISBANE, CALIFORNIA, May 15, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics bas
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
05:00pm, Tuesday, 26'th Mar 2024
BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics b
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
11:00am, Thursday, 01'st Feb 2024
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics ba
BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisory firms, Institutional Shareholde
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
09:30am, Monday, 04'th Dec 2023
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's
GT Biopharma Reports Third Quarter 2023 Financial Results
09:00am, Wednesday, 01'st Nov 2023
BRISBANE, CALIFORNIA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics ba
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:16am, Thursday, 24'th Aug 2023
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
GT Biopharma Reports Second Quarter 2023 Financial Results
09:00am, Monday, 07'th Aug 2023
C ash of approximately $ 1 8.0 million as of June 30 , 202 3 , provide s ample runway to fund operations into Q 3 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and initiat
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
01:25pm, Thursday, 03'rd Aug 2023
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
11:09am, Friday, 02'nd Jun 2023
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
01:46pm, Friday, 19'th May 2023
GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
